| Identification | Back Directory | [Name]
4-Morpholineethanamine, N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)- | [CAS]
1281681-54-6 | [Synonyms]
VP3.15
VP-3.15,VP3.15
4-Morpholineethanamine, N-(2,3-diphenyl-1,2,4-thiadiazol-5(2H)-ylidene)- | [Molecular Formula]
C20H22N4OS | [MDL Number]
MFCD32197300 | [MOL File]
1281681-54-6.mol | [Molecular Weight]
366.48 |
| Chemical Properties | Back Directory | [Boiling point ]
505.1±60.0 °C(Predicted) | [density ]
1.25±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
Soluble in DMSO | [pka]
6.44±0.10(Predicted) |
| Hazard Information | Back Directory | [Uses]
VP3.15 is a potent, orally bioavailable and CNS-penetrant dual phosphodiesterase (PDE)7- glycogen synthase kinase (GSK)3 inhibitor, with IC50s of 1.59 μM and 0.88 μM for PDE7 and GSK-3, respectively. VP3.15 has neuroprotective and neuroreparative activities, thus as potential combined anti-inflammatory and pro-remyelinating therapies for multiple sclerosis (MS)[1]. | [References]
[1] Medina-Rodríguez EM, et al. Promoting in vivo remyelination with small molecules: a neuroreparative pharmacological treatment for Multiple Sclerosis. Sci Rep. 2017 Mar 3;7:43545. DOI:10.1038/srep43545 |
|
|